Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($4.17) for the year, up from their prior forecast of ($4.24). The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share.
JSPR has been the subject of several other reports. Royal Bank of Canada lowered their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research note on Thursday, January 9th. BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. HC Wainwright reduced their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, January 10th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $38.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $62.50.
Get Our Latest Research Report on Jasper Therapeutics
Jasper Therapeutics Trading Down 1.7 %
NASDAQ JSPR traded down $0.09 during trading hours on Thursday, hitting $5.28. The company's stock had a trading volume of 246,948 shares, compared to its average volume of 266,384. The company has a market capitalization of $79.21 million, a PE ratio of -1.11 and a beta of 2.23. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01. The company's 50-day simple moving average is $7.99 and its two-hundred day simple moving average is $16.28.
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35).
Institutional Investors Weigh In On Jasper Therapeutics
Several large investors have recently modified their holdings of JSPR. BNP Paribas Financial Markets lifted its stake in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new stake in Jasper Therapeutics in the 4th quarter worth about $223,000. Finally, Jane Street Group LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at about $251,000. Hedge funds and other institutional investors own 79.85% of the company's stock.
About Jasper Therapeutics
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Read More
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
